Quest Diagnostics stock reaches new highs as Apple Health lab deal and analyst upgrades lift sentiment

Published on 09/16/2026 at 11:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Quest Diagnostics stock climbed to a new 52-week high near USD 248.65 as of September 15, 2026, helped by momentum around its Apple Health lab testing launch. Analyst price targets up to USD 250 and raised 2026 EPS guidance underpin the valuation.

Automatisierter Laboranalysator mit Blutproben-Röhrchen in klinischem Diagnostiklabor — Quest Diagnostics US74834L1008 zeigt automatisierten Laboranalysator mit Blutproben in modernem Diagnostiklabor fotorealistisch dargestellt, Illustration mit AI erstellt.

Quest Diagnostics Incorporated stock (ISIN US74834L1008) is trading near a new high, with the shares around USD 247.96 on the New York Stock Exchange as of September 15, 2026, up roughly 42.9 percent year to date according to data summarized by MarketBeat.

Apple Health lab integration drives attention

Investor interest in Quest Diagnostics has intensified after the company announced on September 9, 2026 that users of the Apple Health app in the United States will be able to order biomarker lab tests directly from Quest and receive results inside the app, expanding its consumer-facing footprint, as reported by MarketBeat.

This consumer-health initiative builds on Quest Diagnostics' broader strategy to grow its direct-to-consumer diagnostics business, which has been described as showing fast growth and stronger utilization alongside its traditional physician and hospital channels, according to analysis cited by Quiver Quant on September 15, 2026.

Conference commentary and guidance support the story

The momentum around Quest Diagnostics stock has also been linked to upbeat management commentary at a global healthcare conference held on September 15, 2026, where executives discussed strategy and performance, highlighting broad-based operational momentum, stronger physician-channel utilization and continued growth in the consumer business, as reflected in coverage of the event by Quiver Quant.

According to MarketBeat on September 15, 2026, Quest Diagnostics has set its full-year 2026 earnings guidance at USD 11.05 to USD 11.25 earnings per share, with equity analysts expecting around USD 11.15 EPS for the year. This implies high single-digit to double-digit growth versus earlier years and gives investors a numerical anchor for the elevated share price.

MarketBeat also notes that Quest Diagnostics shares rose 4.3 percent in mid-day trading on September 15, 2026, with the stock reaching an intraday high of USD 246.56 and last trading around USD 248.01, compared with a prior close of USD 237.89 on the same exchange. That single-session advance of more than 4 percent reinforced the stock's climb toward its 52-week high near USD 248.65 reported by MarketBeat.

Analyst price targets move higher

Analyst houses have responded to Quest Diagnostics' execution and outlook with a series of price target increases. As Investing.com reported on September 15, 2026, Truist Securities raised its price target on Quest Diagnostics from USD 225 to USD 250 while maintaining a Hold rating, and UBS lifted its target from USD 232 to USD 245 with a Neutral stance after meetings with management that reviewed year-to-date performance and prospects.

In addition, according to a research note cited by MarketBeat on September 16, 2026, UBS Group reiterated its Neutral rating alongside the higher USD 245 objective. MarketBeat further summarizes that one analyst currently rates Quest Diagnostics stock as Strong Buy, five assign Buy and seven Hold, for a consensus rating of Moderate Buy and an average price target around USD 236.31.

These revised targets put the top-of-range analyst view at USD 250 compared with a recent closing level near USD 247.96, leaving limited numerical upside but signalling confidence that the company can sustain its earnings trajectory. For investors, the key quantitative takeaway is that the consensus target of roughly USD 236.31 now sits about 4.7 percent below the recent share price, while Truist's upgraded USD 250 target is modestly above it, underscoring that Quest Diagnostics stock is trading at the upper end of analysts' valuation ranges.

Dividend and yield add an income component

Quest Diagnostics also offers an income stream that complements its growth story. As highlighted by MarketBeat, the company declared a quarterly cash dividend of USD 0.86 per share to be paid on October 21, 2026 to shareholders of record on October 6, 2026, with an ex-dividend date also on October 6, 2026. This equates to an annualized dividend of USD 3.44 and a dividend yield of around 1.4 percent based on recent share prices, with a payout ratio presently near 36.52 percent.

For investors, that payout ratio suggests Quest Diagnostics retains a majority of its earnings to reinvest in its laboratory network, digital initiatives and potential acquisitions while still returning cash to shareholders. The combination of moderate yield and rising earnings guidance is one reason the stock has been able to sustain a strong year-to-date performance of about 42.9 percent from a starting level near USD 173.47, as summarized by MarketBeat.

Risks: valuation and execution

Despite the positive narrative, several risks stand out. First, valuation has become more demanding as the stock has approached and briefly touched an all-time high near USD 247.30, a level noted in coverage by Investing.com. With the consensus price target now below the market price, any disappointment on earnings, guidance or the rollout of the Apple Health partnership could trigger volatility.

Second, the consumer diagnostics initiative inside Apple Health must execute smoothly to justify the implied growth expectations. As Quiver Quant notes, the move into app-based biomarker testing is a significant expansion of Quest Diagnostics' consumer-facing reach, but it also introduces new competition dynamics and technology integration risks.

Finally, while analyst sentiment is broadly supportive, the presence of multiple Hold and Neutral ratings from firms such as UBS and Truist Securities underlines that not all observers see Quest Diagnostics stock as deeply undervalued at current levels, as reflected in their revised but still cautious targets cited by Investing.com.

Quest Diagnostics stock near its 52-week high

As of the close on September 15, 2026, Quest Diagnostics stock was quoted around USD 247.96 on the New York Stock Exchange, with a 52-week range from approximately USD 171.18 to USD 248.65 and a market capitalization near USD 27.28 billion, based on the overview compiled by MarketBeat. That places the current share price effectively at the top of its one-year trading band, underscoring how strongly Quest Diagnostics stock has responded to the combination of raised 2026 EPS guidance, the Apple Health lab testing launch and recent analyst target revisions.